Hemab Therapeutics Reports Second Quarter 2026 Financial Results And Provides Corporate Update
COAG•Second-quarter results and corporate update
Aug. 11 (Reuters) - Hemab Therapeutics Holdings Inc COAG.O:
- Hemab Therapeutics reports second quarter 2026 financial results and provides corporate update
- Hemab Therapeutics - Q2 net loss $24.20 million, or $0.80 per share
Related News
Catheter Precision unit Flyte partners with Nucleus Network for inaugural founder-investor event
VTAK•
FibroBiologics wins US patent on fibroblast-assisted islet transplant engraftment for Type 1 diabetes
FBLG•
